Milestones, Momentum,
& What’s Next
strategic partnerships, clinical advancements, and market milestones.
Stay informed as PanGIA Biotech advances its mission to
make early cancer detection more accessible, accurate, and globally scalable.
PanGIA Biotech to Present Four Abstracts at ISLB 2025 Showcasing Multi-Disease Detection Capabilities
PanGIA’s scalable technology demonstrates ability to detect disease-specific molecular patterns across multiple clinical biofluids October 30, 2025 MIAMI, Fla. — October 30, 2025 — PanGIA
The Future of Multi-Cancer Diagnostics — Built for Care, Ready for Integration
In the interview, Curtiss explained why PanGIA Biotech is advancing a platform for true Multi-Cancer Early Detection (MCED) using urine as the biospecimen. He emphasized how co-development with oncologists ensures results that integrate directly into patient care.
PanGIA Biotech Featured in 360Dx for Advancing Urine-Based Prostate Cancer Test
PanGIA Biotech was featured in GenomeWeb’s 360Dx for its AI-powered approach to non-invasive prostate cancer detection using urine samples.
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®’s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample.
PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research
PanGIA’s AI-enabled urine-based liquid biopsy will be featured in a poster session at ASCO 2025. The collaborative study highlights progress toward earlier, non-invasive detection of high-grade prostate cancer.
PanGIA Biotech Expands Leadership Team, Appoints Curtiss McNair as Vice President of Operations
PanGIA strengthens its operational leadership with the appointment of Curtiss McNair to oversee clinical lab operations, infrastructure, and systems integration as the company prepares for commercial scale.